CMPX on XNAS, Health Care, Compass Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Shares fell 86% in a year, a delisting notice arrived, and 23% of shares are sold short.
BadInstitutional holders fell 19%, from 211 filers to 170
BadNet loss of $86.4M over 12 months, with $163.1M cash
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 5 Jan 2027 (an estimate: a year ago it reported on 6 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $27.2M.
31 Dec 2021RevenueNet incomeNet losstallest bar $27.2M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$27.2M
30 Jun 2026
–
-$25.2M
31 Mar 2026
–
-$18.3M
31 Dec 2025
$0
-$15.7M
30 Sep 2025
$0
-$14.3M
30 Jun 2025
$0
-$19.9M
31 Mar 2025
–
-$16.6M
31 Dec 2024
$0
-$15.0M
30 Sep 2024
$0
-$10.5M
30 Jun 2024
$850K
-$13.1M
31 Mar 2024
–
-$10.8M
31 Dec 2023
$0
-$13.4M
30 Sep 2023
$0
-$10.0M
30 Jun 2023
$0
-$11.3M
31 Mar 2023
–
-$7.8M
31 Dec 2022
–
-$11.6M
30 Sep 2022
–
-$12.0M
30 Jun 2022
–
-$8.5M
31 Mar 2022
–
-$7.2M
31 Dec 2021
–
-$13.0M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$86.4M
-$65.8M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-49.0%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$163.1M
$219.9M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$163.1M (net cash)
-$219.9M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$0.79
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.87
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$27K
bought $27K, sold $0
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-19%
170 13F filers vs 211
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
88%
159.1M shares held by 13F filers (30 Sep 2026) of 180.1M outstanding (5 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
23%
40.8M shares sold short (30 Oct 2026) of 180.1M outstanding (5 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
18.9
40.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-2.5%
41.8M shares sold short in the report before, 40.8M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
39%
39% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 45%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
18
18 articles in the last 7 days; its usual week has 6.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
2.8×
18 articles in the last 7 days; its usual week has 6.5.
Price $0.69 on 20 Nov 2026, -86% over 12 months (12-month range $0.61 to $6.69)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $27K in the last 12 months (the 12 months before: -$5.6M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).Revenue per quarter. Revenue $0 in the latest quarter.Capital spending per quarter. Capital spending $106K in the latest quarter, +1414% on a year earlier.Institutional holders (13F filers). 170 13F filers reported holding it in the latest 13F quarter, +43% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 30 Jun 2023: $0; public on 13 Aug 2024
Quarter ended 30 Sep 2023: $0; public on 13 Nov 2024
Quarter ended 31 Dec 2023: $0; public on 28 Feb 2025
Quarter ended 30 Jun 2024: $850K; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $0; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $0; public on 28 Feb 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 6 Mar 2026
Capital spending per quarter
Quarter ended 20 Jun 2021: $296K; public on 2 Aug 2022
Quarter ended 31 Dec 2021: $777K; public on 19 Mar 2022
Quarter ended 31 Mar 2022: $194K, +52% on a year earlier; public on 10 May 2022
Quarter ended 30 Sep 2022: $27K, -93% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $54K, -93% on a year earlier; public on 16 Mar 2023
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $11K; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $10K, -63% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $9K, -83% on a year earlier; public on 22 Mar 2024
Quarter ended 31 Mar 2024: $0; public on 9 May 2025
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $44K, +340% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $0, -100% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $18K; public on 9 May 2025
Quarter ended 30 Sep 2025: $7K, -84% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Mar 2026: $82K, +356% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $176K; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $106K, +1414% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 35; public on 14 Feb 2022
31 Mar 2022 report: 33; public on 16 May 2022
30 Jun 2022 report: 32; public on 15 Aug 2022
30 Sep 2022 report: 36; public on 14 Nov 2022
31 Dec 2022 report: 52; public on 14 Feb 2023
31 Mar 2023 report: 69; public on 15 May 2023
30 Jun 2023 report: 69; public on 14 Aug 2023
30 Sep 2023 report: 73; public on 14 Nov 2023
31 Dec 2023 report: 70; public on 14 Feb 2024
31 Mar 2024 report: 75; public on 15 May 2024
30 Jun 2024 report: 77; public on 14 Aug 2024
30 Sep 2024 report: 77; public on 14 Nov 2024
31 Dec 2024 report: 91; public on 14 Feb 2025
31 Mar 2025 report: 105; public on 15 May 2025
30 Jun 2025 report: 99; public on 14 Aug 2025
30 Sep 2025 report: 119; public on 14 Nov 2025
31 Dec 2025 report: 164; public on 17 Feb 2026
31 Mar 2026 report: 195; public on 15 May 2026
30 Jun 2026 report: 211; public on 14 Aug 2026
30 Sep 2026 report: 170; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $22.0M (30 Sep 2026), 1.7× its normal quarter; higher than 100% of its own history.
Two or more unrelated kinds of records unusual within 30 days
15 May 2025confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Compass Therapeutics(CMPX): had 7.6M shares sold short in the 30 Apr 2025 report, 4.6× the same report last year, while it saw 25 13F filers open a new position in the quarter ended 31 Mar 2025, 2.8× the same quarter last year. Two unrelated kinds of activity within 105 days.
Short interest and volume: Short interest spike, became public on 10 Apr 2025
Short interest and volume: Short interest spike, became public on 26 Apr 2025
Short interest and volume: Short interest spike, became public on 10 May 2025
Institutional holdings: Many funds opening a new position, became public on 15 May 2025
Short interest and volume: Short interest spike, became public on 28 May 2025
Short interest and volume: Short interest spike, became public on 11 Jun 2025
Short interest and volume: Short interest spike, became public on 26 Jun 2025
Short interest and volume: Short interest spike, became public on 25 Jul 2025
The 30 Apr 2025 report against the 24 reports before it.
this reportearliernormal: 2.1MSee the evidence (8 changes)
Short interest and volume: Short interest spike became public on 10 Apr 2025
Compass Therapeutics had 6.6M shares sold short in the 31 Mar 2025 report, 4.1× the same report last year.
This period
6.6M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
304K
How far from its usual level
+10.5
Same report last year
1.6M
History used
1,431 days
the 31 Mar 2025 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Apr 2025
Compass Therapeutics had 8.2M shares sold short in the 15 Apr 2025 report, 5.1× the same report last year.
This period
8.2M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
343K
How far from its usual level
+12.2
Same report last year
1.6M
History used
1,446 days
the 15 Apr 2025 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 May 2025
Compass Therapeutics had 7.6M shares sold short in the 30 Apr 2025 report, 4.6× the same report last year.
This period
7.6M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
427K
How far from its usual level
+8.8
Same report last year
1.6M
History used
1,461 days
the 30 Apr 2025 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2025
Compass Therapeutics saw 25 13F filers open a new position in the quarter ended 31 Mar 2025, 2.8× the same quarter last year.
This period
25 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+3.9
Same quarter last year
9
History used
1,186 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 10.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 28 May 2025
Compass Therapeutics had 6.9M shares sold short in the 15 May 2025 report, 4.2× the same report last year.
This period
6.9M (the 15 May 2025 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
545K
How far from its usual level
+5.9
Same report last year
1.6M
History used
1,476 days
the 15 May 2025 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jun 2025
Compass Therapeutics had 7.4M shares sold short in the 30 May 2025 report, 4.8× the same report last year.
This period
7.4M (the 30 May 2025 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
583K
How far from its usual level
+6.0
Same report last year
1.6M
History used
1,491 days
the 30 May 2025 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jun 2025
Compass Therapeutics had 7.4M shares sold short in the 13 Jun 2025 report, 4.7× the same report last year.
This period
7.4M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
583K
How far from its usual level
+5.9
Same report last year
1.6M
History used
1,505 days
the 13 Jun 2025 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Jul 2025
Compass Therapeutics had 7.8M shares sold short in the 15 Jul 2025 report, 3.9× the same report last year.
This period
7.8M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
876K
How far from its usual level
+4.0
Same report last year
2.0M
History used
1,537 days
the 15 Jul 2025 report24 earlier reportsnormal: 2.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
saw 47 13F filers open a new position in the quarter ended 31 Dec 2025, 3.4× the same quarter last year.
Same quarter last year: 14; its normal quarter is 12.5.
See the evidence
This period
47 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
12.5
Typical spread (median absolute deviation)
3.5
How far from its usual level
+6.6
Same quarter last year
14
History used
1,461 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 12.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 27 13F filers open a new position in the quarter ended 30 Sep 2025, 2.7× the same quarter last year.
Same quarter last year: 10; its normal quarter is 10.5.
See the evidence
This period
27 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+4.5
Same quarter last year
10
History used
1,369 days
the quarter ended 30 Sep 20258 earlier quartersnormal: 10.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 7.8M shares sold short in the 15 Jul 2025 report, 3.9× the same report last year.
Same report last year: 2.0M; its normal report is 2.6M.
See the evidence
This period
7.8M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
876K
How far from its usual level
+4.0
Same report last year
2.0M
History used
1,537 days
the 15 Jul 2025 report24 earlier reportsnormal: 2.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.4M shares sold short in the 13 Jun 2025 report, 4.7× the same report last year.
Same report last year: 1.6M; its normal report is 2.3M.
See the evidence
This period
7.4M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
583K
How far from its usual level
+5.9
Same report last year
1.6M
History used
1,505 days
the 13 Jun 2025 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.4M shares sold short in the 30 May 2025 report, 4.8× the same report last year.
Same report last year: 1.6M; its normal report is 2.2M.
See the evidence
This period
7.4M (the 30 May 2025 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
583K
How far from its usual level
+6.0
Same report last year
1.6M
History used
1,491 days
the 30 May 2025 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.9M shares sold short in the 15 May 2025 report, 4.2× the same report last year.
Same report last year: 1.6M; its normal report is 2.2M.
See the evidence
This period
6.9M (the 15 May 2025 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
545K
How far from its usual level
+5.9
Same report last year
1.6M
History used
1,476 days
the 15 May 2025 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.6M shares sold short in the 30 Apr 2025 report, 4.6× the same report last year, while it saw 25 13F filers open a new position in the quarter ended 31 Mar 2025, 2.8× the same quarter last year. Two unrelated kinds of activity within 105 days.
See the evidence (8 changes)
Short interest and volume: Short interest spike became public on 10 Apr 2025
Compass Therapeutics had 6.6M shares sold short in the 31 Mar 2025 report, 4.1× the same report last year.
This period
6.6M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
304K
How far from its usual level
+10.5
Same report last year
1.6M
History used
1,431 days
the 31 Mar 2025 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Apr 2025
Compass Therapeutics had 8.2M shares sold short in the 15 Apr 2025 report, 5.1× the same report last year.
This period
8.2M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
343K
How far from its usual level
+12.2
Same report last year
1.6M
History used
1,446 days
the 15 Apr 2025 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 May 2025
Compass Therapeutics had 7.6M shares sold short in the 30 Apr 2025 report, 4.6× the same report last year.
This period
7.6M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
427K
How far from its usual level
+8.8
Same report last year
1.6M
History used
1,461 days
the 30 Apr 2025 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2025
Compass Therapeutics saw 25 13F filers open a new position in the quarter ended 31 Mar 2025, 2.8× the same quarter last year.
This period
25 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+3.9
Same quarter last year
9
History used
1,186 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 10.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 28 May 2025
Compass Therapeutics had 6.9M shares sold short in the 15 May 2025 report, 4.2× the same report last year.
This period
6.9M (the 15 May 2025 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
545K
How far from its usual level
+5.9
Same report last year
1.6M
History used
1,476 days
the 15 May 2025 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jun 2025
Compass Therapeutics had 7.4M shares sold short in the 30 May 2025 report, 4.8× the same report last year.
This period
7.4M (the 30 May 2025 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
583K
How far from its usual level
+6.0
Same report last year
1.6M
History used
1,491 days
the 30 May 2025 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jun 2025
Compass Therapeutics had 7.4M shares sold short in the 13 Jun 2025 report, 4.7× the same report last year.
This period
7.4M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
583K
How far from its usual level
+5.9
Same report last year
1.6M
History used
1,505 days
the 13 Jun 2025 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Jul 2025
Compass Therapeutics had 7.8M shares sold short in the 15 Jul 2025 report, 3.9× the same report last year.
This period
7.8M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
876K
How far from its usual level
+4.0
Same report last year
2.0M
History used
1,537 days
the 15 Jul 2025 report24 earlier reportsnormal: 2.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 May 2025Institutional holdings change
saw 25 13F filers open a new position in the quarter ended 31 Mar 2025, 2.8× the same quarter last year.
Same quarter last year: 9; its normal quarter is 10.5.
See the evidence
This period
25 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+3.9
Same quarter last year
9
History used
1,186 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 10.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 7.6M shares sold short in the 30 Apr 2025 report, 4.6× the same report last year.
Same report last year: 1.6M; its normal report is 2.1M.
See the evidence
This period
7.6M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
427K
How far from its usual level
+8.8
Same report last year
1.6M
History used
1,461 days
the 30 Apr 2025 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.2M shares sold short in the 15 Apr 2025 report, 5.1× the same report last year.
Same report last year: 1.6M; its normal report is 2.0M.
See the evidence
This period
8.2M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
343K
How far from its usual level
+12.2
Same report last year
1.6M
History used
1,446 days
the 15 Apr 2025 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.6M shares sold short in the 31 Mar 2025 report, 4.1× the same report last year.
Same report last year: 1.6M; its normal report is 1.9M.
See the evidence
This period
6.6M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
304K
How far from its usual level
+10.5
Same report last year
1.6M
History used
1,431 days
the 31 Mar 2025 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.6M shares sold short in the 14 Mar 2025 report, 2.4× the same report last year.
Same report last year: 1.9M; its normal report is 1.9M.
See the evidence
This period
4.6M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
269K
How far from its usual level
+6.9
Same report last year
1.9M
History used
1,414 days
the 14 Mar 2025 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.7M shares sold short in the 28 Feb 2025 report, 2.0× the same report last year.
Same report last year: 1.8M; its normal report is 1.8M.
See the evidence
This period
3.7M (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
243K
How far from its usual level
+5.1
Same report last year
1.8M
History used
1,400 days
the 28 Feb 2025 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.5M shares sold short in the 14 Feb 2025 report, 1.8× the same report last year.
Same report last year: 2.0M; its normal report is 1.8M.
See the evidence
This period
3.5M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
228K
How far from its usual level
+5.0
Same report last year
2.0M
History used
1,386 days
the 14 Feb 2025 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.2M shares sold short in the 15 Jan 2025 report, 1.6× the same report last year.
Same report last year: 2.0M; its normal report is 1.8M.
See the evidence
This period
3.2M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
219K
How far from its usual level
+4.1
Same report last year
2.0M
History used
1,356 days
the 15 Jan 2025 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.3M shares sold short in the 30 Jun 2023 report, 41× the same report last year.
Same report last year: 106K; its normal report is 625K.
See the evidence
This period
4.3M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
625K
Typical spread (median absolute deviation)
583K
How far from its usual level
+4.2
Same report last year
106K
History used
791 days
the 30 Jun 2023 report24 earlier reportsnormal: 625K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.2M shares sold short in the 15 Jun 2023 report, 26× the same report last year.
Same report last year: 84K; its normal report is 254K.
See the evidence
This period
2.2M (the 15 Jun 2023 report)
Normal report (median of 24 earlier)
254K
Typical spread (median absolute deviation)
225K
How far from its usual level
+5.9
Same report last year
84K
History used
776 days
the 15 Jun 2023 report24 earlier reportsnormal: 254K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.0M shares sold short in the 31 May 2023 report, 13× the same report last year.
Same report last year: 157K; its normal report is 181K.
See the evidence
This period
2.0M (the 31 May 2023 report)
Normal report (median of 24 earlier)
181K
Typical spread (median absolute deviation)
139K
How far from its usual level
+9.0
Same report last year
157K
History used
761 days
the 31 May 2023 report24 earlier reportsnormal: 181K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.1M shares sold short in the 15 May 2023 report, 8.9× the same report last year.
Same report last year: 231K; its normal report is 181K.
See the evidence
This period
2.1M (the 15 May 2023 report)
Normal report (median of 24 earlier)
181K
Typical spread (median absolute deviation)
134K
How far from its usual level
+9.5
Same report last year
231K
History used
745 days
the 15 May 2023 report24 earlier reportsnormal: 181K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.2M shares sold short in the 28 Apr 2023 report, 17× the same report last year.
Same report last year: 127K; its normal report is 162K.
See the evidence
This period
2.2M (the 28 Apr 2023 report)
Normal report (median of 24 earlier)
162K
Typical spread (median absolute deviation)
113K
How far from its usual level
+12.1
Same report last year
127K
History used
728 days
the 28 Apr 2023 report24 earlier reportsnormal: 162K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.1M shares sold short in the 14 Apr 2023 report, 13× the same report last year.
Same report last year: 162K; its normal report is 159K.
See the evidence
This period
2.1M (the 14 Apr 2023 report)
Normal report (median of 24 earlier)
159K
Typical spread (median absolute deviation)
97K
How far from its usual level
+13.4
Same report last year
162K
History used
714 days
the 14 Apr 2023 report24 earlier reportsnormal: 159K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.0M shares sold short in the 31 Mar 2023 report, 2.7× the same report last year.
Same report last year: 748K; its normal report is 159K.
See the evidence
This period
2.0M (the 31 Mar 2023 report)
Normal report (median of 24 earlier)
159K
Typical spread (median absolute deviation)
97K
How far from its usual level
+12.8
Same report last year
748K
History used
700 days
the 31 Mar 2023 report24 earlier reportsnormal: 159K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.1M shares sold short in the 15 Mar 2023 report, 2.8× the same report last year.
Same report last year: 754K; its normal report is 159K.
See the evidence
This period
2.1M (the 15 Mar 2023 report)
Normal report (median of 24 earlier)
159K
Typical spread (median absolute deviation)
97K
How far from its usual level
+13.7
Same report last year
754K
History used
684 days
the 15 Mar 2023 report24 earlier reportsnormal: 159K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 106 entries; narrow the window or the kind of data to see older ones.
Not listed: 77 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it